These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27699578)

  • 21. Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis.
    Lee JW; Kang JH; Yim YR; Kim JE; Wen L; Lee KE; Park DJ; Kim TJ; Park YW; Lee SS
    PLoS One; 2015; 10(7):e0131864. PubMed ID: 26176701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
    Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
    Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
    Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
    J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.
    Lee H; Park HY; Jeon K; Jeong BH; Hwang JW; Lee J; Cha HS; Koh EM; Kang ES; Koh WJ
    PLoS One; 2015; 10(3):e0119260. PubMed ID: 25746854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
    Liao TL; Lin CH; Chen YM; Chang CL; Chen HH; Chen DY
    PLoS One; 2016; 11(4):e0153217. PubMed ID: 27064275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?
    Lauper K; Kearsley-Fleet L; Galloway JB; Watson KD; ; Hyrich KL; Lunt M
    Rheumatology (Oxford); 2024 Jul; 63(7):1957-1964. PubMed ID: 37758229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.
    Boqaeid A; Layqah L; Alonazy A; Althobaiti M; Almahlawi AZ; Al-Roqy A; Baharoon O; Alsaeedi A; Shamou J; Baharoon S
    J Infect Public Health; 2024 Jun; 17(6):1134-1141. PubMed ID: 38728834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.